Monte Rosa Therapeutics, Inc.
GLUE
$16.86
$1.459.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.50% | 59.44% | 246.66% | 140.41% | 31.60% |
| Total Depreciation and Amortization | 1.90% | 19.55% | -1.82% | 31.60% | 14.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.70% | 11.57% | -9.84% | 1.11% | -24.66% |
| Change in Net Operating Assets | 5,098.60% | -881.44% | -664.73% | 90.03% | -155.59% |
| Cash from Operations | 578.37% | -25.04% | -19.20% | 335.05% | 15.02% |
| Capital Expenditure | -63.16% | 16.17% | -14.67% | 89.17% | 75.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.68% | 145.69% | -977.83% | -292.12% | 2.31% |
| Cash from Investing | 1.03% | 141.41% | -1,117.24% | -316.10% | 5.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,220.00% | -99.29% | -94.31% | 110.38% | -98.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | 2,220.00% | -99.63% | -94.31% | -97.58% | -98.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 728.35% | -199.26% | -419.16% | 42.73% | 39.48% |